Clinical Trial Update: Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial (OPTIMIZE-GNI) to optimize beta-lactam dosing in critically ill patients using cystatin C, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infection

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Bacterial Infection | Phase 4 | Status: RECRUITING